Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by National Bank of Canada FI

National Bank of Canada FI boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 66.3% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 71,159 shares of the biopharmaceutical company's stock after acquiring an additional 28,365 shares during the quarter. National Bank of Canada FI owned 0.06% of Regeneron Pharmaceuticals worth $74,805,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp raised its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock valued at $5,153,603,000 after acquiring an additional 61,277 shares during the last quarter. International Assets Investment Management LLC raised its stake in Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock valued at $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company's stock valued at $707,759,000 after purchasing an additional 11,499 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Regeneron Pharmaceuticals by 12.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company's stock worth $567,864,000 after purchasing an additional 59,769 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Regeneron Pharmaceuticals by 23.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company's stock worth $525,804,000 after buying an additional 96,266 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating on the stock in a research note on Friday, November 1st. Morgan Stanley decreased their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. StockNews.com downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $1,107.29.

Regeneron Pharmaceuticals Trading Up 1.3 %

Shares of NASDAQ REGN traded up $10.10 during trading on Friday, reaching $778.00. The stock had a trading volume of 813,640 shares, compared to its average volume of 785,952. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company has a market cap of $85.49 billion, a P/E ratio of 19.25, a PEG ratio of 2.91 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $735.95 and a fifty-two week high of $1,211.20. The business's 50-day moving average price is $876.85 and its 200-day moving average price is $1,011.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.